Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NBRV | Ordinary Shares | Award | $0 | +17.5K | $0.00 | 17.5K | Jul 28, 2021 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NBRV | Share Options | Award | $0 | +35.5K | $0.00 | 35.5K | Jul 28, 2021 | Ordinary Shares | 35.5K | $1.08 | Direct | F2, F3 |
Id | Content |
---|---|
F1 | The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units. |
F2 | The option was granted on July 28, 2021. |
F3 | One hundred percent (100%) of the option will vest on July 31, 2022, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc. |